{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:33Z","timestamp":1790797053345,"version":"4.1.0"},"reference-count":244,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":322,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different clinical settings and always require an individually tailored approach. This is the reason why a panel of Italian neuroendocrine experts was charged with the task to provide indications for the diagnostic and therapeutic approaches that can be easily applied in different contexts. The document provides 15 recommendations for diagnosis and 54 recommendations for treatment, issued according to the GRADE system. The level of agreement among panel members was formally evaluated by RAND-UCLA methodology. In the last century, prolactinomas represented the paradigm of pituitary tumors for which the development of highly effective drugs obtained the best results, allowing to avoid neurosurgery in most cases. The impressive improvement of neurosurgical endoscopic techniques allows a far better definition of the tumoral tissue during surgery and the remission of endocrine symptoms in many patients with pituitary tumors. Consequently, this refinement of neurosurgery is changing the therapeutic strategy in prolactinomas, allowing the definitive cure of some patients with permanent discontinuation of medical therapy.<\/jats:p>","DOI":"10.1530\/eje-21-0977","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:49:30Z","timestamp":1641804570000},"page":"P1-P33","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":65,"title":["Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors"],"prefix":"10.1093","volume":"186","author":[{"given":"Renato","family":"Cozzi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Niguarda Hospital , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara , Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1417-287X","authenticated-orcid":false,"given":"Roberto","family":"Attanasio","sequence":"additional","affiliation":[{"name":"AME Scientific Committee , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Battista","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, IRCCS Casa Sollievo della Sofferenza Hospital , San Giovanni Rotondo (FG), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bozzao","sequence":"additional","affiliation":[{"name":"Neuroradiology, S. Andrea Hospital, NESMOS Department (Neuroscience, Mental Health, Sensorial Organs), Sapienza University of Rome , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caputo","sequence":"additional","affiliation":[{"name":"Laboratorio Analisi Cliniche e Microbiologia, Synlab SRL , Calenzano, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Endocrinology, Ospedale Martini, ASL Citt\u00e0 di Torino , Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[{"name":"Pituitary Unit, Department of Endocrinology, Catholic University of the Sacred Heart, School of Medicine , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"De Menis","sequence":"additional","affiliation":[{"name":"Internal Medicine 2, Treviso Hospital , Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Faustini Fustini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna , Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"AME President, Endocrinology and Metabolism Unit, University Hospital S. Maria della Misericordia , Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lania","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Endocrinology Unit , Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lasio","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS , Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Logoluso","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Bisceglie Hospital, ASLBT , Bisceglie, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Losa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Gamma Knife Radiosurgery, IRCCS San Raffaele Scientific Institute, Vita-Salute University , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Maffei","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), 3rd Medical Clinic, Padua University Hospital , Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS , Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poggi","sequence":"additional","affiliation":[{"name":"Endocrinology, Department of Clinical and Molecular Medicine, S. Andrea Hospital, Sapienza University of Rome , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Zini","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Azienda Ospedaliera S. Maria Nuova IRCCS , Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Katznelson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University Hospital , Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Medical University of Vienna , Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Poiana","sequence":"additional","affiliation":[{"name":"\u2018Carol Davila\u2019 University of Medicine and Pharmacy \u2013 Endocrinology, \u201cC.I. Parhon\u201d National Institute of Endocrinology \u2013 Pituitary and Neuroendocrine Disorders , Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-16-0087","article-title":"Therapy of endocrine disease \u2013 surgery in microprolactinomas: effectiveness and risks based on contemporary literature","volume":"175","author":"Tampourlou","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathologica"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","article-title":"A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system","volume":"93","author":"Swiglo","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023021911585297200_","volume-title":"The Rand\/UCLA Appropriateness Method User's Manual","author":"Fitch","year":"2021"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Practice and Research: Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000497746","article-title":"Epidemiology and management challenges in prolactinomas","volume":"109","author":"Vroonen","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/eje.1.02107","article-title":"Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data","volume":"154","author":"Buurman","year":"2006","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinemia","volume":"8","author":"Samperi","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000495184","article-title":"Giant prolactinomas","volume":"109","author":"Shimon","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000497205","article-title":"Aggressive and malignant prolactinomas","volume":"109","author":"Olarescu","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ncl.2016.06.014","article-title":"Epidemiology of brain tumors","volume":"34","author":"McNeill","year":"2016","journal-title":"Neurologic Clinics"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00431-017-3042-5","article-title":"Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis","volume":"177","author":"Hoffmann","year":"2018","journal-title":"European Journal of Pediatrics"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1210\/jc.2014-3670","article-title":"Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients","volume":"100","author":"Salenave","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1530\/EC-17-0171","article-title":"Morbidity and mortality in patients with hyperprolactinemia: the PROLEARS study","volume":"6","author":"Soto-Pedre","year":"2017","journal-title":"Endocrine Connections"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clineuro.2018.11.024","article-title":"Fertility after transsphenoidal surgery in patients with prolactinomas: a meta-analysis","volume":"176","author":"Lamba","year":"2019","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clinic Proceedings"},{"key":"2023021911585297200_","first-page":"265","article-title":"New insights in prolactin: pathological implications","volume":"11","author":"Bernard","year":"2015","journal-title":"Nature Reviews: Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM197703172961103","article-title":"Galactorrhea: a study of 235 cases, including 48 with pituitary tumors","volume":"296","author":"Kleinberg","year":"1977","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","first-page":"1073","article-title":"Evaluation and management of galactorrhea","volume":"85","author":"Huang","year":"2012","journal-title":"American Family Physician"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: clinical and biochemical features and response to treatment","volume":"20","author":"De Rosa","year":"2003","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh","year":"2015","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000236081","article-title":"Prolactinoma in children and adolescents","volume":"72","author":"Fideleff","year":"2009","journal-title":"Hormone Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.eprac.2020.09.001","article-title":"Association between prolactinoma and body mass index","volume":"27","author":"Al Sabie","year":"2021","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","article-title":"Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term","volume":"24","author":"Andereggen","year":"2021","journal-title":"Journal of Clinical and Translational Endocrinology"},{"key":"2023021911585297200_","first-page":"392","article-title":"Prolactinoma and body weight: a retrospective study","volume":"125","author":"Creemers","year":"1991","journal-title":"Acta Endocrinologica"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/neuros\/nyy087","article-title":"Contribution of intrasellar pressure elevation to headache manifestation in pituitary adenoma evaluated with intraoperative pressure measurement","volume":"84","author":"Hayashi","year":"2019","journal-title":"Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11916-012-0267-x","article-title":"How to investigate and treat: headache and hyperprolactinemia","volume":"16","author":"Bussone","year":"2012","journal-title":"Current Pain and Headache Reports"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0333102413515343","article-title":"Prolactinoma-associated headache and dopamine agonist treatment","volume":"34","author":"Kallestrup","year":"2014","journal-title":"Cephalalgia"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/brain\/awh525","article-title":"The clinical characteristics of headache in patients with pituitary tumours","volume":"128","author":"Levy","year":"2005","journal-title":"Brain"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11102-018-0907-1","article-title":"Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review","volume":"21","author":"\u010ces\u00e1k","year":"2018","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coemr.2018.02.006","article-title":"Prolactinoma and bone","volume":"3","author":"Chiloiro","year":"2018","journal-title":"Current Opinion in Endocrine and Metabolic Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","article-title":"Hyperprolactinemia and bone","volume":"23","author":"Di Filippo","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ecl.2014.10.014","article-title":"Pituitary diseases and bone","volume":"44","author":"Mazziotti","year":"2015","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-0630-1529","article-title":"Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma","volume":"50","author":"Ozer","year":"2018","journal-title":"Hormone and Metabolic Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","article-title":"The effects of hyperprolactinemia on bone and fat","volume":"12","author":"Shibli-Rahhal","year":"2009","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11102-007-0064-4","article-title":"Bone density in women with prolactinoma treated with dopamine agonists","volume":"11","author":"Naliato","year":"2008","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.1988.tb01195.x","article-title":"Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women","volume":"28","author":"Ciccarelli","year":"1988","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"14","author":"Mazziotti","year":"2011","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0300-0664.2001.01464.x","article-title":"Fracture risk is increased in patients with GH deficiency or untreated prolactinomas \u2013 a case-control study","volume":"56","author":"Vestergaard","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato","year":"2008","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/EJE-07-0259","article-title":"Quality of life is decreased in female patients treated for microprolactinoma","volume":"157","author":"Kars","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-14-0941","article-title":"Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas","volume":"172","author":"Leistner","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/cen.13915","article-title":"Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas","volume":"90","author":"Vega-Beyhart","year":"2019","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"236","DOI":"10.20945\/2359-3997000000032","article-title":"Controversial issues in the management of hyperprolactinemia and prolactinomas \u2013 an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism","volume":"62","author":"Vilar","year":"2018","journal-title":"Archives of Endocrinology and Metabolism"},{"key":"2023021911585297200_","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1055\/s-0034-1389925","article-title":"Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma","volume":"46","author":"Lombardi","year":"2014","journal-title":"Hormone and Metabolic Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the diagnostic evaluation of hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.177.4055.1205","article-title":"Human prolactin: 24-hour pattern with increased release during sleep","volume":"177","author":"Sassin","year":"1972","journal-title":"Science"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4158\/EP-2020-0260","article-title":"Role of cannulated prolactin test in evaluation of hyperprolactinemia \u2013 a retrospective study","volume":"26","author":"Tsur","year":"2020","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","first-page":"65","article-title":"Macro-enzymes: prevalence, composition, detection and clinical relevance","volume":"28","author":"Sturk","year":"1990","journal-title":"Journal of Clinical Chemistry and Clinical Biochemistry"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1373\/49.9.1504","article-title":"Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactinemia screening","volume":"49","author":"Suliman Am","year":"2003","journal-title":"Clinical Chemistry"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1258\/0004563053857969","article-title":"Macroprolactin; high molecular mass forms of circulating prolactin","volume":"42","author":"Fahie-Wilson","year":"2005","journal-title":"Annals of Clinical Biochemistry"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2265.2005.02243.x","article-title":"Clinical relevance of macro-prolactin","volume":"62","author":"Gibney","year":"2005","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-005-9108-7","article-title":"Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of \u2018hook effect\u2019","volume":"79","author":"Fleseriu","year":"2006","journal-title":"Journal of Neuro-Oncology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1515\/cclm-2016-1183","article-title":"High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference","volume":"55","author":"Piketty","year":"2017","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s12020-020-02497-w","article-title":"Hyperprolactinemia: still an insidious diagnosis","volume":"72","author":"Aliberti","year":"2021","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000503256","article-title":"Clinically nonfunctioning pituitary incidentalomas: characteristics and natural history","volume":"110","author":"Tresoldi","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40618-020-01338-x","article-title":"The prevalence of silent acromegaly in prolactinomas is very low","volume":"44","author":"Bona","year":"2021","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023021911585297200_","first-page":"OC30","article-title":"Correlation of serum prolactin level to Child Pugh scoring system in cirrhosis of liver","volume":"11","author":"Balakrishnan","year":"2017","journal-title":"Journal of Clinical and Diagnostic Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hdi.12489","article-title":"Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis","volume":"21","author":"Lo","year":"2017","journal-title":"Hemodialysis International: International Symposium on Home Hemodialysis"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s11102-017-0833-7","article-title":"Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms","volume":"20","author":"De Sousa","year":"2017","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4158\/EP.12.1.29","article-title":"Pituitary enlargement in patients with primary hypothyroidism","volume":"12","author":"Khawaja","year":"2006","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","article-title":"Management of antipsychotic-induced hyperprolactinemia","volume":"6","author":"Tewksbury","year":"2016","journal-title":"Mental Health Clinician"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"C11","DOI":"10.1530\/EJE-20-0607","article-title":"Dopamine agonists and antipsychotics","volume":"183","author":"Molitch","year":"2020","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s004040050261","article-title":"Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic regulation as possible etiology","volume":"263","author":"Alvarez-Tutor","year":"1999","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/jc.2011-2976","article-title":"Approach to the patient with persistent hyperprolactinemia and negative sellar imaging","volume":"97","author":"Glezer","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa1307557","article-title":"Mutant prolactin receptor and familial hyperprolactinemia","volume":"369","author":"Newey","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"101278","DOI":"10.1016\/j.beem.2019.05.002","article-title":"Modern imaging of pituitary adenomas","volume":"33","author":"Bashari","year":"2019","journal-title":"Best Practice and Research: Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12020-016-1038-y","article-title":"Pituitary magnetic resonance imaging in Cushing's disease","volume":"55","author":"Vitale","year":"2017","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone-producing and nongrowth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","article-title":"T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists","volume":"63","author":"Burlacu","year":"2019","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3174\/ajnr.A0692","article-title":"Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging","volume":"28","author":"Tosaka","year":"2007","journal-title":"American Journal of Neuroradiology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2016-2008","article-title":"Dopamine agonists can reduce cystic prolactinomas","volume":"101","author":"Faje","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"138","DOI":"10.11604\/pamj.2019.33.138.12897","article-title":"Extensive sphenoid chordoma mimicking a prolactinoma","volume":"33","author":"El Euch","year":"2019","journal-title":"Pan African Medical Journal"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"Journal of Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-10-0255","article-title":"Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients","volume":"163","author":"Brochier","year":"2010","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.wneu.2017.09.017","article-title":"Radiological predictors for extent of resection in pituitary adenoma surgery. A single-center study","volume":"108","author":"Sanmill\u00e1n","year":"2017","journal-title":"World Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2013-1249","article-title":"The prevalence and natural history of pituitary hemorrhage in prolactinoma","volume":"98","author":"Sarwar","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"Journal of Neuro-Oncology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11102-013-0473-5","article-title":"Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?","volume":"17","author":"Alkabbani","year":"2014","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging in the management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-16-0897","article-title":"MRI follow-up is unnecessary in patients with macro-prolactinomas and long-term normal prolactin levels on dopamine agonist treatment","volume":"176","author":"Eroukhmanoff","year":"2017","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"Supplement","key":"2023021911585297200_","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"Journal of Reproductive Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiol.2018181151","article-title":"Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA Workshop on Gadolinium chelates","volume":"289","author":"McDonald","year":"2018","journal-title":"Radiology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical Practice Guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the Dutch MEN1 study group (DMSG)","volume":"100","author":"De Laat","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1507\/endocrj.42.413","article-title":"Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies","volume":"42","author":"Eguchi","year":"1995","journal-title":"Endocrine Journal"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200342070-00003","article-title":"Clinical pharmacokinetics of cabergoline","volume":"42","author":"Del Dotto","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.4158\/EP10369.CR","article-title":"Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas","volume":"17","author":"Iyer","year":"2011","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2165\/00003495-199651060-00004","article-title":"Diagnosis and drug therapy of prolactinoma","volume":"51","author":"Ciccarelli","year":"1996","journal-title":"Drugs"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocrine Reviews"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cen.13399","article-title":"Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes","volume":"87","author":"Santharam","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","article-title":"The role of dopamine agonists in pituitary adenomas","volume":"49","author":"Giraldi","year":"2020","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"e4558","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4158\/EP15804.OR","article-title":"Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas","volume":"21","author":"Tirosh","year":"2015","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","article-title":"Early prediction of long-term response to cabergoline in patients with macroprolactinomas","volume":"29","author":"Lee","year":"2014","journal-title":"Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-19-0753","article-title":"Prolactin \u22641 ng\/mL predicts macroprolactinoma reduction after cabergoline therapy","volume":"182","author":"Kim","year":"2020","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EJE-21-0561","article-title":"Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline","volume":"185","author":"Biagetti","year":"2021","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","first-page":"82","article-title":"Diagnostic values of beta-2 transferrin and beta-trace protein as markers for cerebrospinal fluid fistula","volume":"46","author":"Bachmann-Harildstad","year":"2008","journal-title":"Rhinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2012.4.FOCUS1268","article-title":"Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature","volume":"32","author":"Lam","year":"2012","journal-title":"Neurosurgical Focus"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline","volume":"104","author":"Stiles","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints","volume":"106","author":"Stiles","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","article-title":"Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2015","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","article-title":"Second attempt to withdraw cabergoline in prolactinomas: a pilot study","volume":"17","author":"Kwancharoen","year":"2014","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2015.00011","article-title":"Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile?","volume":"6","author":"Vilar","year":"2015","journal-title":"Frontiers in Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-016-1159-3","article-title":"Mortality in adults with hypopituitarism: a systematic review and meta-analysis","volume":"56","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jsxm.2018.04.641","article-title":"Testosterone and cardiovascular risk: meta-analysis of interventional studies","volume":"15","author":"Corona","year":"2018","journal-title":"Journal of Sexual Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones?","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ando.2007.03.008","article-title":"Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy","volume":"68","author":"Christin-Ma\u00eetre","year":"2007","journal-title":"Annales d'Endocrinologie"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-017-1438-7","article-title":"Prolactinoma through the female life cycle","volume":"59","author":"Cocks Eschler","year":"2018","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"e4551","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12020-019-01962-5","article-title":"Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years","volume":"65","author":"Shimon","year":"2019","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-64-2-391","article-title":"Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen","volume":"64","author":"Prior","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma","volume":"87","author":"Gillam","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","article-title":"Surgery for prolactinomas: a better choice?","volume":"23","author":"Honegger","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/jnnp-2012-303194","article-title":"Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis","volume":"84","author":"Ammirati","year":"2013","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"2023021911585297200_","first-page":"1","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","article-title":"Transsphenoidal microsurgical results of female patients with prolactinomas","volume":"115","author":"Ikeda","year":"2013","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome","volume":"87","author":"Losa","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1227\/01.NEU.0000325725.77132.90","article-title":"Pituitary hormonal loss and recovery after transsphenoidal adenoma removal","volume":"63","author":"Fatemi","year":"2008","journal-title":"Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","article-title":"Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists","volume":"14","author":"Babey","year":"2011","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jocn.2009.03.024","article-title":"Non-surgical management of cystic prolactinomas","volume":"16","author":"Bahuleyan","year":"2009","journal-title":"Journal of Clinical Neuroscience"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11102-016-0766-6","article-title":"Significance of surgical management for cystic prolactinoma","volume":"20","author":"Ogiwara","year":"2017","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11102-018-0888-0","article-title":"Management of cystic prolactinomas: a review","volume":"21","author":"Nakhleh","year":"2018","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(82)92756-8","article-title":"Bromocriptine: does it jeopardise the result of later surgery for prolactinomas?","volume":"2","author":"Landolt","year":"1982","journal-title":"Lancet"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4158\/EP13165.RA","article-title":"Effect of the preoperative use of dopamine agonists in the postoperative course of prolactinomas: a systematic review","volume":"20","author":"Carija","year":"2014","journal-title":"Endocrine Practice"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","article-title":"Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States","volume":"87","author":"Jethwa","year":"2016","journal-title":"World Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11102-011-0348-6","article-title":"Radiotherapy for prolactin-secreting pituitary tumors","volume":"15","author":"Sheplan Olsen","year":"2012","journal-title":"Pituitary"},{"key":"2023021911585297200_","first-page":"1","article-title":"The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study","volume":"133","author":"Hung","year":"2019","journal-title":"Journal of Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s11102-015-0658-1","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results","volume":"18","author":"Cohen-Inbar","year":"2015","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11102-019-00971-x","article-title":"Role of gamma knife radiosurgery in the treatment of prolactinomas","volume":"22","author":"Je\u017ekov\u00e1","year":"2019","journal-title":"Pituitary"},{"issue":"Supplement 1","key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/2018.7.GKS181595","article-title":"Neurocognitive changes in pituitary adenoma patients after gamma knife radiosurgery","volume":"129","author":"Tooze","year":"2018","journal-title":"Journal of Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(18)30659-4","article-title":"Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicenter, cohort study","volume":"20","author":"Wolf","year":"2019","journal-title":"Lancet: Oncology"},{"issue":"Supplement 1","key":"2023021911585297200_","first-page":"108","article-title":"Prolactin excess: treatment and toxicity","volume":"2","author":"Gillam","year":"2004","journal-title":"Pediatric Endocrinology Reviews"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/JPEM.2000.13.3.261","article-title":"Peripubertal prolactinomas: clinical presentation and longterm outcome with different therapeutic approaches","volume":"13","author":"Fideleff","year":"2000","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-10-0519","article-title":"Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes","volume":"163","author":"Steele","year":"2010","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fendo.2020.00527","article-title":"Clinical, hormonal, and neuroradiological characteristics and therapeutic outcomes of prolactinomas in children and adolescents at a single center","volume":"11","author":"Yang","year":"2020","journal-title":"Frontiers in Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1072-7515(01)01101-2","article-title":"The surgical management of pituitary adenomas in a series of 3,093 patients","volume":"193","author":"Jane","year":"2001","journal-title":"Journal of the American College of Surgeons"},{"key":"2023021911585297200_","first-page":"91","article-title":"Pediatric pituitary adenoma: case series, review of the literature, and a skull base treatment paradigm","volume":"79","author":"Perry","year":"2018","journal-title":"Journal of Neurological Surgery: Part B, Skull Base"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9378(82)90641-X","article-title":"Oral contraceptives and prolactinomas: a case-control study","volume":"143","author":"Maheux","year":"1982","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0010-7824(83)90057-4","article-title":"Oral contraceptive steroids do not promote the development or growth of prolactinomas","volume":"27","author":"Hulting","year":"1983","journal-title":"Contraception"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertility and Sterility"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ajo.13070","article-title":"An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists","volume":"60","author":"O'Sullivan","year":"2020","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14767058.2017.1402000","article-title":"Placental transfer of bromocriptine in an ex vivo human placental perfusion model","volume":"32","author":"Zheng","year":"2019","journal-title":"Journal of Maternal-Fetal and Neonatal Medicine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cen.14162","article-title":"Evolution of macroprolactinomas during pregnancy: a cohort study of 85 pregnancies","volume":"92","author":"Barraud","year":"2020","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2016.12126","article-title":"Association between MRI exposure during pregnancy and fetal and childhood outcomes","volume":"316","author":"Ray","year":"2016","journal-title":"JAMA"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-020-01107-2","article-title":"Management of sellar and parasellar tumors becoming symptomatic during pregnancy: a practical algorithm based on multi-center experience and systematic literature review","volume":"24","author":"Zoli","year":"2021","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11102-019-01004-3","article-title":"Surgical indications for pituitary tumors during pregnancy: a literature review","volume":"23","author":"Graillon","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-21-0145","article-title":"Apoplexy of microprolactinomas during pregnancy. Report of five cases and review of the literature","volume":"185","author":"Kuhn","year":"2021","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","article-title":"Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation","volume":"98","author":"Auriemma","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant'Anna","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine treated mothers","volume":"22","author":"Raymond","year":"1985","journal-title":"Hormone Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12020-014-0334-7","article-title":"Prolactinomas, cabergoline, and pregnancy","volume":"47","author":"Glezer","year":"2014","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management?","volume":"23","author":"Greenman","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","first-page":"695","article-title":"Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine\/paracrine loop","volume":"146","author":"Clevenger","year":"1995","journal-title":"American Journal of Pathology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semcdb.2020.10.005","article-title":"Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis","volume":"114","author":"Karayazi At\u0131c\u0131","year":"2021","journal-title":"Seminars in Cell and Developmental Biology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Research"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"pky055","DOI":"10.1093\/jncics\/pky055","article-title":"Inclusion of plasma prolactin levels in current risk prediction models of premenopausal and postmenopausal breast cancer","volume":"2","author":"Gabrielson","year":"2018","journal-title":"JNCI Cancer Spectrum"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-15-0282","article-title":"Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature","volume":"173","author":"Dekkers","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/bcp.13661","article-title":"Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study","volume":"84","author":"Pottegard","year":"2018","journal-title":"British Journal of Clinical Pharmacology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.genhosppsych.2007.11.002","article-title":"Cabergoline-induced psychotic exacerbation in schizophrenic patients","volume":"30","author":"Chang","year":"2008","journal-title":"General Hospital Psychiatry"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03345068","article-title":"Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders","volume":"23","author":"Tollin","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/EJE-20-0125","article-title":"Efficacy and safety of dopamine agonists in patients treated with antipsychotic and presenting a macroprolactinoma","volume":"183","author":"Allard","year":"2020","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03345523","article-title":"Prevalence of osteopenia in men with prolactinoma","volume":"28","author":"Naliato","year":"2005","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023021911585297200_","first-page":"745","article-title":"Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: a systematic review and meta-analysis","volume":"36","author":"D'Sylva","year":"2015","journal-title":"Neuro Endocrinology Letters"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12020-014-0377-9","article-title":"Treatment of hyperprolactinemia in post-menopausal women: pros","volume":"48","author":"Iacovazzo","year":"2015","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026225625897","article-title":"Dopamine resistance of prolactinomas","volume":"6","author":"Molitch","year":"2003","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12020-018-1703-4","article-title":"Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses","volume":"62","author":"Araujo","year":"2018","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocrine Disorders"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12020-017-1486-z","article-title":"Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma","volume":"60","author":"Del Gatto","year":"2018","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","article-title":"Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma","volume":"14","author":"Fusco","year":"2011","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocrine Connections"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4103\/0028-3886.84332","article-title":"Microsurgical management of prolactinomas-clinical and hormonal outcome in a series of 172 cases","volume":"59","author":"Sinha","year":"2011","journal-title":"Neurology India"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","article-title":"Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas","volume":"19","author":"Shimon","year":"2016","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-10-0961","article-title":"Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases","volume":"164","author":"Qu","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"Journal of Neurosurgery"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11102-017-0848-0","article-title":"Excellence in the treatment of patients with pituitary tumors","volume":"21","author":"Molitch","year":"2018","journal-title":"Pituitary"},{"key":"2023021911585297200_","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11102-018-0904-4","article-title":"The experience with transsphenoidal surgery and its importance to outcomes","volume":"21","author":"Honegger","year":"2018","journal-title":"Pituitary"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/186\/3\/EJE-21-0977.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/186\/3\/P1\/49174930\/eje-21-0977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/186\/3\/P1\/49174930\/eje-21-0977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T15:59:49Z","timestamp":1700063989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/186\/3\/P1\/6954267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":244,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-21-0977","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2022,2,3]]}}}